PURPOSE: Macrophage colony-stimulating factor-1 receptor (CSF-1R) is a transmembrane tyrosine kinase receptor, which is abnormally expressed in invasive breast cancer. Small cohort studies have demonstrated that increased expression of CSF-1R is associated with ipsilateral breast cancer recurrence. Correlation with survival has not been reported. Our aim was to further evaluate the role of CSF-1R in breast cancer, by studying the expression of CSF-1R in a large cohort of clinical specimens. EXPERIMENTAL DESIGN: Tissue microarrays containing 301 node-negative and 280 node-positive cases were used. Immunohistochemical staining was performed and correlated with overall survival, nodal status, and other clinicopathological data. RESULTS: CSF-1R expression was strongly associated with nodal status. Of the node-negative cases, 114 (38.9%) stained positive for CSF-1R, whereas 189 (67.5%) of the node-positive cases expressed CSF-1R (P < 0.0001). CSF-1R expression is also associated with larger tumor size (P = 0.02). Positive staining was strongly associated with decreased survival (P = 0.0003). Among node-negative patients, CSF-1R expression was associated with decreased overall survival (P = 0.045), whereas among node-positive patients, it was not (P = 0.47). In multivariate analysis, CSF-1R was not independent of nodal status as a predictor of survival. CONCLUSIONS: CSF-1R expression is a strong predictor of poor outcome in nonmetastatic breast cancer. It is significantly more frequently expressed in patients with nodal involvement. Among the node-negative patients, it has a stronger association with survival than among the node-positive patients. Our findings support other preclinical findings that CSF-1R may be involved in local invasion and metastasis. Thus, this receptor may be an effective target for therapeutic agents.
PURPOSE:Macrophage colony-stimulating factor-1 receptor (CSF-1R) is a transmembrane tyrosine kinase receptor, which is abnormally expressed in invasive breast cancer. Small cohort studies have demonstrated that increased expression of CSF-1R is associated with ipsilateral breast cancer recurrence. Correlation with survival has not been reported. Our aim was to further evaluate the role of CSF-1R in breast cancer, by studying the expression of CSF-1R in a large cohort of clinical specimens. EXPERIMENTAL DESIGN: Tissue microarrays containing 301 node-negative and 280 node-positive cases were used. Immunohistochemical staining was performed and correlated with overall survival, nodal status, and other clinicopathological data. RESULTS:CSF-1R expression was strongly associated with nodal status. Of the node-negative cases, 114 (38.9%) stained positive for CSF-1R, whereas 189 (67.5%) of the node-positive cases expressed CSF-1R (P < 0.0001). CSF-1R expression is also associated with larger tumor size (P = 0.02). Positive staining was strongly associated with decreased survival (P = 0.0003). Among node-negative patients, CSF-1R expression was associated with decreased overall survival (P = 0.045), whereas among node-positive patients, it was not (P = 0.47). In multivariate analysis, CSF-1R was not independent of nodal status as a predictor of survival. CONCLUSIONS:CSF-1R expression is a strong predictor of poor outcome in nonmetastatic breast cancer. It is significantly more frequently expressed in patients with nodal involvement. Among the node-negative patients, it has a stronger association with survival than among the node-positive patients. Our findings support other preclinical findings that CSF-1R may be involved in local invasion and metastasis. Thus, this receptor may be an effective target for therapeutic agents.
Authors: Björn Lamprecht; Korden Walter; Stephan Kreher; Raman Kumar; Michael Hummel; Dido Lenze; Karl Köchert; Mohamed Amine Bouhlel; Julia Richter; Eric Soler; Ralph Stadhouders; Korinna Jöhrens; Kathrin D Wurster; David F Callen; Michael F Harte; Maciej Giefing; Rachael Barlow; Harald Stein; Ioannis Anagnostopoulos; Martin Janz; Peter N Cockerill; Reiner Siebert; Bernd Dörken; Constanze Bonifer; Stephan Mathas Journal: Nat Med Date: 2010-05-02 Impact factor: 53.440
Authors: Lisa Volk-Draper; Radhika Patel; Nihit Bhattarai; Jie Yang; Andrew Wilber; David DeNardo; Sophia Ran Journal: Am J Pathol Date: 2019-08-15 Impact factor: 4.307
Authors: Jonathan A Webster; Andrew H Beck; Mimansa Sharma; Inigo Espinosa; Britta Weigelt; Marthe Schreuder; Kelli D Montgomery; Kristin C Jensen; Matt van de Rijn; Robert West Journal: J Pathol Date: 2010-10 Impact factor: 7.996
Authors: Eugene P Toy; Masoud Azodi; Nancy L Folk; Christina M Zito; Caroline J Zeiss; Setsuko K Chambers Journal: Neoplasia Date: 2009-02 Impact factor: 5.715
Authors: Kenneth D Bromberg; Harriet M Kluger; Agnes Delaunay; Sabiha Abbas; Kyle A DiVito; Stan Krajewski; Ze'ev Ronai Journal: Cancer Res Date: 2007-09-01 Impact factor: 12.701